Robust Diagnostic and Therapeutic Biomarkers for Tuberculosis Identified Through Multi‐Omics and Mendelian Randomization Analysis
MedComm · 2026-01 · 7 (1)
DOI: 10.1002/mco2.70559 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 29.12.2025. Verfasst von Chenglin Zhu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences Henan University Kaifeng Henan People's Republic of China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tuberculosis (TB) remains a major global health challenge. In this study, we applied UPLC‐MS/MS lipidomics and data‐independent acquisition proteomics to profile plasma from healthy controls, active TB patients, and cured individuals to identify differentially expressed lipids and proteins. Mendelian randomization prioritized phosphatidylcholine (PC) lipids (PC(18:2/18:2), PC(14:0/20:4) and PC(18:0/20:4)) and proteins (haptoglobin [HP], retinol binding protein 4 [RBP4], coagulation factor XIII B subunit [F13B] and inter‐alpha‐trypsin inhibitor heavy chain 1 [ITIH1]) as candidate diagnostic and cure biomarkers. Binary multi‐omics random‐forest classifiers constructed with these markers achieved strong diagnostic (AUC = 0.967, 95% CI: 0.928–1.000) and cure‐monitoring (AUC = 0.981, 95% CI: 0.956–1.000) performance, which was further assessed with ten‐fold cross‐validation. Integration with transcriptomic data and lipid‐related gene analysis provided additional molecular support for HP. Independent validation in the GSE34608 cohort (AUC = 0.965) and ELISA verification (AUC = 0.969) confirmed HP's diagnostic utility at gene and protein levels. GSVA enrichment implicated HP in iron homeostasis and immune response pathways, suggesting a role in Mycobacterium tuberculosis infection and immune evasion through modulation of host iron metabolism. Overall, we present a robust lipid–protein biomarker panel and accurate multi‐omics models for TB diagnosis and monitoring of cure, and propose HP as a promising biomarker and potential therapeutic target. These tools may improve clinical management and treatment evaluation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Basic Medical Sciences Henan University Kaifeng Henan People's Republic of China.
- Clinical Laboratory Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University Linhai Zhejiang Province People's Republic of China.
- Department of Clinical Laboratory The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou People's Republic of China.
Zitieren
APA
Zhu, C., Chen, J., Li, Y., Zhang, Q., Lu, Q., Zhang, N., Fan, H., Khakwani, M. M. A. K., Zhang, L., & Li, J. C. (2026). Robust Diagnostic and Therapeutic Biomarkers for Tuberculosis Identified Through Multi‐Omics and Mendelian Randomization Analysis. MedComm, 7(1). https://doi.org/10.1002/mco2.70559
Vancouver
Zhu C, Chen J, Li Y, Zhang Q, Lu Q, Zhang N, et al. Robust Diagnostic and Therapeutic Biomarkers for Tuberculosis Identified Through Multi‐Omics and Mendelian Randomization Analysis. MedComm. 2026;7(1). doi:10.1002/mco2.70559
BibTeX
@article{Zhu2026,
author = {Zhu, Chenglin and Chen, Jiaxi and Li, Ying and Zhang, Qi and Lu, Qiqi and Zhang, Ningxuan and Fan, Hao and Khakwani, Muhammad Mahtab Aslam Khan and Zhang, Lei and Li, Ji-Cheng},
title = {Robust Diagnostic and Therapeutic Biomarkers for Tuberculosis Identified Through Multi‐Omics and Mendelian Randomization Analysis},
journal = {MedComm},
year = {2026},
volume = {7},
number = {1},
doi = {10.1002/mco2.70559}
}
EUVIMED